Production (Stage)
Atea Pharmaceuticals, Inc.
AVIR
$2.90
$0.051.75%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | 19.06% | -11.76% | -14.65% | -13.83% | -23.35% |
| Gross Profit | -19.06% | 11.76% | 14.65% | 13.83% | 23.35% |
| SG&A Expenses | -6.98% | -2.14% | -7.35% | -1.90% | 1.53% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -11.31% | 31.48% | 28.34% | 32.37% | 28.12% |
| Operating Income | 11.31% | -31.48% | -28.34% | -32.37% | -28.12% |
| Income Before Tax | 14.77% | -24.10% | -32.60% | -59.91% | -44.29% |
| Income Tax Expenses | -14.73% | -9.14% | 32.45% | 132.00% | 131.01% |
| Earnings from Continuing Operations | 14.77% | -23.85% | -32.60% | -65.80% | -49.73% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 14.77% | -23.85% | -32.60% | -65.80% | -49.73% |
| EBIT | 11.31% | -31.48% | -28.34% | -32.37% | -28.12% |
| EBITDA | 11.34% | -31.58% | -28.44% | -32.48% | -28.15% |
| EPS Basic | 15.73% | -22.67% | -31.63% | -64.91% | -49.17% |
| Normalized Basic EPS | 10.15% | -42.90% | -34.39% | -33.65% | -20.52% |
| EPS Diluted | 15.73% | -22.67% | -31.63% | -64.91% | -49.17% |
| Normalized Diluted EPS | 10.15% | -42.90% | -34.39% | -33.65% | -20.52% |
| Average Basic Shares Outstanding | 1.24% | 1.05% | 0.78% | 0.52% | 0.30% |
| Average Diluted Shares Outstanding | 1.24% | 1.05% | 0.78% | 0.52% | 0.30% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |